Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors

Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development

Volumn , Issue , 2006, Pages 307-331

  Alonso, Diana ^a   Martínez, Ana ^a  

^a NeuroPharma   (Spain)

Author keywords

Genisteine and isoflavones; Hymenialdisine and pyrrole alkaloids; Marine compounds new source for GSK 3 inhibitors

Indexed keywords

EID: 84947313609     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470052171.ch16     Document Type: Chapter

References (64)

1. Cohen P., Frame S. (2001). The renaissance of GSK-3. Nat. Rev. Mol. Cell. Biol., 2, 769-776.
2. Nikoulina S.E., Ciaraldi T.P., Mudailar S., Mohideen P., Carter L., Henry R.R. (2000). Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes, 49, 263-271.
3. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M., Hanger D., Mulot S., Marquardt B. (1994). Alzheimer's disease-like phosphorylation of the microtubule-associated protein Tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol., 4, 1077-1086.
4. Martinez A., Castro A., Dorronsoro I., Alonso M. (2002). Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and infl ammation. Med. Res. Rev., 22, 373-384.
5. Naerum L., Norskov-Lauritsen L., Olesen P.H. (2002). Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett., 12, 1525-1528.
6. Coghlan M.P., Culbert A.A., Cross D.A.E., Corcoran S.L., Yates J.D., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Cox L.R., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., Holder J. (2000). Selective small molecule inhibitors of glycogen synthase kinase 3 modulate glycogen metabolism and gene transcription. Chem. Biol., 7, 793-803.
7. Alonso M., Martinez A. (2004). GSK-3 inhibitors: Discoveries and developments. Curr. Med. Chem., 11, 755-763.
8. Meijer L., Flajolet M., Greengard P. (2004). Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci., 2, 471-480.
9. Dorronsoro I., Castro A., Martinez A. (2002). Inhibitors of Glycogen Synthase Kinase 3 (GSK-3): Future drugs for the treatment of unmet diseases? Exp. Opin. Ther. Patent, 12, 1527-1536.
10. Frenz J.L., Col A.C., Kerr R.G. (2004). Marine natural products as therapeutic agents: Part 2. Expert Opin. Ther. Patents, 14, 17-33.
11. Alonso D., Castro A., Martinez A. (2005). Marine compounds for the therapeutic treatment of neurological disorders. Exp. Opin. Ther. Patents, 15, 1377-1386.
12. Williams D.H., Faulkner J. (1996). Isomers and tautomers of hymenialdisine and debromohymenialfisine. Nat. Prod. Lett., 9, 57-64.
13. Cimino G., De Rosa S., De Stefano S., Mazzarella L., Puliti R., Sodano. (1982). Isolation and X-ray cristal structure of a novel bromo-compound from two marine sponges. Tetrahedrom Lett., 23, 767-768.
14. Meijer L. (2001). WO 01/041768. Use of hymenialdisine or derivatives thereof in the manufacture of medicaments.
15. Tasdemir D., Mallon R., Greenstein M., Felderg L.R., Kim S.C., Collins K., Wojciechowicz D., Mangalindan G., Concepción G., Harper M.K., Ireland C.M. (2002). Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of nitogen-activated protein kinase-1 (MEK-1). J. Med. Chem., 45, 529-532.
16. Sharma V., Tepr J.J., (2004). Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg. Med. Chem. Lett., 14, 4319-4321.
17. Meijer L., Thunnissen A.-M.W.H., White A.W., Garnier M., Nikolic M., Tsai L.H., Walter J., Cleverley K.E., Salinas P.C., Wu Y.Z., Biernat J., Mandelkow E.M., Kim S.H., Pettit G.R. (2001). Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol., 7, 51-63.
18. Sharma V., Lansdell T.A., Jin G., Tepe J.J. (2004). Inhibition of cytokine production by hymenialdisine derivatives. J. Med. Chem., 47, 3700-3703.
19. Bretón J., Chabot-Fletcher M.C. (1997). The natural product hymenialdisine ihbibits intelukin-8 production in U937 cells by inhibition of nuclear factor-B. J. Pharmacol. Exp. Ther., 282, 459-466.
20. Roshak A., Jackson J.R., Chabot-Fletcher M., Marshall L.A. (1997). Inhibition of NFΚB-mediated interleukin-1b-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine. J. Pharmacol. Exp. Ther., 283, 955-996.
21. Annoura H., Tatsuaka T. (1995). Total synthesis of hymenialdisine and debromohymenialsisine. Tetrahedrom Lett., 36, 413-416.
22. Xu Y.-H., Yakushijin K., Horne D.A. (1997). Synthesis of C11N5 marine sponges alkaloids. J. Org. Chem., 62, 456-464.
23. Wan Y., Hur W., Cho Y.C., Liu Y., Adria F., Lozach O., Bacch S., Mayer T., Fabbro D., Meijer L., Gray N. (2004). Synthesis and target identification of hymenialdidine analogs. Chem. Biol., 11, 247-259.
24. Papeo G., Posteri H., Borghi D., Varasi M. (2005). A new glycociamidine ring precursor: Syntheses of (Z)-hymenialdisine, (Z)-2-debromohymenialdisine, and (+/-)-endo-2-debromohymenialdisine. Org. Lett., 7, 5641-5644.
25. Hibino S., Chosi T. (2002). Simple indole alkaloids and those with a nonrearranged monoterpenoid unit. Nat. Prod. Rep., 19, 148-180.
26. Hernández L., Bal de Kier E., Puricelli L., Tatian M., Seldes A.M., Palermo J. (1998). Indole alkaloids from the tunicate Aplidium meridianum. J. Nat. Prod., 61, 1130-1132.
27. Gompel M., Leost M., Bal de Kier E., Puricelli L., Hernández Franco L., Palermo J., Meijer L. (2004). Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. Bioorg. Med. Chem. Lett., 14, 1703-1707.
28. Doble B.W., Woodgett J.R. (2003). GSK-3: Tricks of the trade for a multi-tasking kinase. J. Cell. Sci., 116, 1175-1186.
29. Knockaert M., Greengard P., Meijer L. (2002). Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci., 23, 417-425.
30. Fresneda P., Molina P., Delgado S., Bleda, J.A. (2000). Synthetic studies towards the 2-aminopyrimidine alkaloids variolins and meridianins from marine origin. Tetrahedron Lett., 41, 4777-4780.
31. Jiang B., Yang C.G. (2000). Synthesis of indolylpyrimidines via cross-coupling of indolylboronic acid with chloropyrimidines: Facile synthesis of meridianin D. Heterocycles, 53, 1489-1498.
32. Karpov A., Merkul E., Rominger F., Müller T. (2005). Concise synthesis of meridianins by carbonylative alkynylation and four component pyrimidine synthesis. Angew. Chem. Int. Ed., 44, 6951-6956.
33. Maugard T., Enaud E., Choisy P., Legoy M.D. (2001). Identification of an indigo precursor from leaves of Isatis tinctoria. Phytochemistry, 58, 897-904.
34. Mcaneil I.A., Ttiong C.L., Minor C., August P.R., Grossman T.H., Loiacono K.A., Lynch B.A., Phillipis T., Sundaramoorthi R., et al. (2001). Expression and isolation of antimicrobial small molecules from soil DNA libraries. J. Mol. Microbiol. Biotechnol., 3, 301-308.
35. Cooksey C.J. (2001). Tyrian purple: 6,6'-Dibromoindigo and related compounds. Mol., 6, 736-769.
36. Von Bayer A., Emmerling P. (1870). Reduction des Isatins zu Indigblau. Ber. Dtsch. chem. Ges., 3, 514-517.
37. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.-M., et al. (2001). Indirubins inhibit glycogen synthase kinase-3b and CDK5/p25, two kinases in abnormal Tau phosphorylation in Alzheimer disease-A property common to most CDK inhibitors. J. Biol. Chem., 276, 251-260.
38. Hoessel R., Leclerc S., Endicott J., Noble M., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. (1999). Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol., 1, 60-67.
39. Wang L., Liu X., Chem R. (2004). US 2004/0225002. Derivatives of indigo and indirubin and methods of treating cancer.
40. Huwe A., Mazitscheck R., Giannis A. (2003). Niedermolekulare Verbindungen als Inhibitoren cyclin-abhangiger Kinasen. Angew. Chem., 115, 2170-2175.
41. Moo M., Lee S. K., Lee J.-W., Song W.K., Kim S.W., Kim J.I., Cho C., Choi S.O., Kim Y.C. (2006). Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities. Bioorg. Med. Chem., 14, 237-246.
42. Hanks S.K., Hunter T. (1995). Protein kinases 6, the eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J., 9, 576-596.
43. Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A.H. (2004). Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med., 10, 55-63.
44. Polychronopoulos P., Magiatis P., Skaltosounis A.L., Myrianthopoulos V., Mikros E., Tarricone A., Musacchino A., Mark Roe S., Pearl L., Greengard P., Meijer L. (2004). Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase 3 and cyclin dependent kinases. J. Med. Chem., 12, 935-946.
45. Meijer L., Skaltosounis A.L., Magiatis P., Polychronopoulos P-. Knockaert M.L., Ryan X., Vonica C.A., Brivanlou A., Dajani R., Crovace C., Tarricone C., Musacchino A., Mark Roe S., Pearl L., Greengard P. (2003). GSK-3-selective inhibitors derived from tyrian purple indirubins. Chem. Biol., 10, 1255-1266.
46. Jautelat R. (Schering Ag). (2002). WO 02100401. Soluble CDK-inhibitory Indirubin derivatives.
47. Sakai R., Higa T., Jefford C.W., Bernardinelli G. (1986). Manzamine A, a novel antitumor alkaloid from a sponge. J. Am. Chem. Soc., 108, 6404.
48. Hu J.F., Hamann M.T., Hill R.S., Kelly M. (2003). In Cordell, G.A., ed., The Manzamine Alkaloids: The Alkaloids, New York: Elsevier Science, 207-285.
49. Peng J., Hu J.-F., Kazi A.B., Li Z., Avery M., Peraud O., Hill R., Franzblau S.G., Zhang F., Schinazi R.F., Wirtz S.S., Tharnish P., Kelly M., Wahyuono S., Hamann M.T. (2003). Manadomanzamines A and B, a novel alkaloid ring system with potent activity against mycobacteria and HIV-1. J. Am. Chem. Soc., 125, 13382.
50. Rao K.V., Donia M.S., Peng J., García-Palomero E., Alonso D., Martínez A., Medina M., Franzblau S.G., Tekwani B.L., Khan S.I., Wahyuono S., Willett C., Hamann M.T. (2006). Manzamine B and E and Ircinal A related alkaloids from an Indonesian Acanthostrong ylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's disease. J. Nat. Prod., in presss.
51. Flaherty D.B., Soria J.P., Tomasiewicz H.G., Wood J.G. (2000). Phosphorylation of human Tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J. Neurosci. Res., 62, 463-472.
52. Alonso D., Dorronsoro I., Martines A., Panizo G., Fuertes A., Perez J., Martín E., Perez D., Medina M. (Neuropharma S.A). (2005). WO 05054221. GSK-3 Inhibitors isolated from marine organisms.
53. Alfano G., Cimino G., De Stefano S. (1979). Palinurin, a new linear sesterterpene from a marine sponge. Experentia, 35, 1135-1137.
54. Issa HH., Tanaka J., Higa T. (2003). New cytotoxic furanosesquiterpenes from an Okinawan marine sponge, Ircinia sp. J. Nat. Prod., 66, 251-254.
55. Buchanan MS., Edser A. (2001). Cheilanthane sesterpenes, protein kinases inhibitors, from a marine sponge of the genus Ircinia. J. Nat. Prod., 64, 300-303.
56. Faulkner J. (1973). Variabilin, an antibiotic from the sponge, Ircinia variabilis Tetrahedron Lett., 14, 3821-3822.
57. El Sayed K., Mayer A.M., Kelly M., Hamann M.T. (1999). The biocatalytic transformation of furan to amide in the bioactive marine natural product palinurin. J. Org. Chem., 64, 9258-9260.
58. Li R., Shen Y. (2005). Estrogens and brain: Synthesis, function and diseases. Front. Biosci., 10, 257-267.
59. LeBlanc E.S., Janowsky J., Chan B.K., Nelson H.D. (2001). Hormone replacement therapy and cognition: Systematic review and metanalysis. JAMA, 285, 1489-1499.
60. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. (1987). Genistein, a specific inhibitor of tyrosine-specific protein kinase. J. Biol. Chem., 262, 5592-5595.
61. Kim H., Xu J., Xia H., Li L., Peterson G., Murphy-Ullrich J., Barnes S. (2001). Actions of the soy phytoestrogen genistein in models of human chronis disease:Potential involvement of transforming growth factor β Biochem. Soc. Trans., 29, 216-222.
62. Gutierrez-Zepeda A., Santell R., Wu Z., Brown M., Wu Y., Khan I., Link C.D., Zhao B., Luo Y. (2005). Soy isofl avone glycitein protects against beta amyloidinduced toxicity and oxidative stress in transgenic Caenorhabditis elegans. BMC Neurosci., 6, 54-63.
63. http://www.clinicaltrials.gov/ct/show/NCT00205179
64. Alonso D., Dorronsoro I., Panizo G., Martin-Aparicio E., Fuertes A., Pérez-Puerto M.J., Medina M., Fernandez-Chimeno R.I., Pérez-Baz J., Martínez A. (2006). glycogen synthase kinase-3β inhibitors from marine origin. 10th International Conference on Alzheimer Diseases and Related Disorders, Madrid.